Hasse C, Zielke A, Klöck G, Barth P, Schlosser A, Zimmermann U, Rothmund M
Department of Surgery, Philipps-University of Marburg, Germany.
J Microencapsul. 1997 Sep-Oct;14(5):617-26. doi: 10.3109/02652049709006814.
Owing to the complexity of the parathyroid hormone's metabolic interactions, clinical hypoparathyroidism is one of the most difficult of all endocrine disorders to treat. Therefore, causative treatment of this disorder by transplantation of parathyroid glands is highly desirable. We have recently documented the long-term in vivo function of iso- and allotransplanted rat parathyroid tissue without systemic immunosuppression in an animal model. In view of the potential clinical use of this method, human parathyroid tissue has been microencapsulated and transplanted over the highest immunological barrier. In a controlled, long-term animal study in the parathyroidectomized rat, the effect of microencapsulation on xenotransplanted human parathyroid tissue was evaluated over 30 weeks (native and microencapsulated parathyroid tissue = 40 rats respectively). Functionally, human parathyroid tissue was able to replace that of the rat. All animals that had received microencapsulated parathyroid tissue were normocalcemic for 16 weeks; 27/40 at the end of the study. In contrast, serum calcium concentrations dropped to post-parathyroidectomy levels within 4 weeks in those animals that had received native tissue only. Histologic evaluation of the explanted, functionally successful xenografts showed vital parathyroid tissue inside intact microcapsules surrounded by a small rim of fibroblasts. Avital fibrotic remnants were demonstrated in animals with non-encapsulated parathyroid tissue. Thus, we have established the feasibility of microencapsulation of human parathyroid tissue, preserving its viability over long periods in vivo even if xenotransplanted. In combination with an improved tissue culture method, transplantation of human parathyroid tissue and maintenance of its physiological function is reproducibly achieved without postoperative systemic immunosuppression over the highest transplantation barrier. This may be a crucial step towards the first clinical application of this method.
由于甲状旁腺激素代谢相互作用的复杂性,临床甲状旁腺功能减退症是所有内分泌疾病中最难治疗的疾病之一。因此,通过甲状旁腺移植对该疾病进行病因治疗是非常可取的。我们最近在动物模型中记录了同种异体和异种移植的大鼠甲状旁腺组织在无全身免疫抑制情况下的长期体内功能。鉴于该方法潜在的临床应用价值,人类甲状旁腺组织已被微囊化并移植到最高免疫屏障之上。在一项对甲状旁腺切除大鼠进行的对照长期动物研究中,在30周内评估了微囊化对异种移植人类甲状旁腺组织的影响(分别有40只大鼠接受天然和微囊化甲状旁腺组织)。从功能上来说,人类甲状旁腺组织能够替代大鼠的甲状旁腺组织。所有接受微囊化甲状旁腺组织的动物在16周内血钙正常;研究结束时40只中有27只血钙正常。相比之下,仅接受天然组织的动物在4周内血清钙浓度降至甲状旁腺切除术后水平。对功能成功的移植到体内的异种移植物进行组织学评估显示,完整的微囊内有存活的甲状旁腺组织,周围有一小圈成纤维细胞。未封装甲状旁腺组织的动物出现了无活力的纤维化残余物。因此,我们已经证实了人类甲状旁腺组织微囊化的可行性,即使进行异种移植,其在体内长时间内仍能保持活力。结合改进的组织培养方法,可在最高移植屏障下实现人类甲状旁腺组织的移植并维持其生理功能,且无需术后全身免疫抑制。这可能是该方法首次临床应用的关键一步。